Ovid De-Risks Its Phase III Angelman Program With EU Angelini Partnership
Executive Summary
You may also be interested in...
With Hopeful Interim Data, Ultragenyx Bets On GeneTx, Angelman Syndrome Candidate
Ultragenyx is buying its Angelman syndrome partner GeneTx for $75m on the heels of an interim Phase I/II readout that shows signs of clinical activity and appears to resolve earlier safety worries.
Ovid Shifts Focus After Angelman Syndrome Drug Disappoints In Phase III
The Phase III clinical trial showed a noticeable placebo effect compared with OV101.
Takeda/Ovid Plan Phase III For Soticlestat In Dravet Syndrome, But Pull Back On LGS
A Phase II trial of the CH24H inhibitor showed a statistically significant benefit in children with the rare epilepsy syndrome Dravet Syndrome, but not in Lennox-Gastaut syndrome (LGS).